Charles River Laboratories International, Inc. (NYSE:CRL) Receives $211.00 Consensus Target Price from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has been assigned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $211.00.

Several equities analysts have weighed in on CRL shares. Morgan Stanley raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $185.00 to $220.00 in a research report on Wednesday, June 17th. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Barclays lifted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Evercore reaffirmed an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th.

Charles River Laboratories International Stock Up 1.4%

NYSE:CRL opened at $215.68 on Monday. Charles River Laboratories International has a 52 week low of $144.26 and a 52 week high of $228.88. The stock’s fifty day moving average is $176.98 and its two-hundred day moving average is $183.36. The stock has a market capitalization of $10.39 billion, a price-to-earnings ratio of -57.36, a price-to-earnings-growth ratio of 2.43 and a beta of 1.46. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the previous year, the firm posted $2.34 earnings per share. The company’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts anticipate that Charles River Laboratories International will post 11.05 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tema Etfs LLC purchased a new stake in Charles River Laboratories International during the 4th quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $42,000. Sfam LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $43,000. Activest Wealth Management grew its position in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its position in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.